Gore BIO-A Tissue Reinforcement shows efficacy in new study

Gore has announced the publication of new study data showing the efficacy of its BIO-A Tissue Reinforcement in the treatment of contaminated wounds.

Final results of a long-term prospective multicentre study have been published in the Annals of Surgery, showing the effectiveness of the biosynthetic mesh in complex ventral hernia repair among patients with contaminated wounds.

Of the more than 100 patients enrolled, improved quality of life and intact hernia repairs were achieved by 83 percent when using Gore's BIO-A Tissue Reinforcement. Typically, in this patient population, the recurrence rate is as high as 30 percent when using a biologic mesh.

The investigators also reported that no biosynthetic required complete removal due to infection, highlighting the improved efficacy and cost saving benefits they can provide.

Ron Anderson, general surgical products business unit leader at Gore, said: "By being both more cost-effective for hospitals and payors while also improving quality of life for patients, Gore BIO-A Tissue Reinforcement is truly advancing healthcare and the way we treat CVH."

This comes after the firm recently commenced patient enrolment for its new Gore RELINE MAX Clinical Study, which is designed to assess the effectiveness of its Viabahn Endoprosthesis.